EU/3/19/2164

Table of contents

About

On 29 May 2019, orphan designation (EU/3/19/2164) was granted by the European Commission to Granzer Regulatory Consulting & Services, Germany, for relacorilant for the treatment of Cushing’s syndrome.

Key facts

Active substance
Relacorilant
Disease / condition
Treatment of Cushing's syndrome
Date of first decision
29/05/2019
Outcome
Positive
EU designation number
EU/3/19/2164

Sponsor's contact details

Dr. Ulrich Granzer
Granzer Regulatory Consulting & Services 
Kistlerhofstrasse 172c
81379 Munich
Germany
Tel. +49 89 7806 89820
E-mail: contact@granzer.biz

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating